An Open Label Randomized Controlled Trial of Ivermectin Plus Favipiravir-Based Standard of Care versus Favipiravir-Based Standard of Care for Treatment of Moderate COVID-19 in Thailand

BACKGROUND: The role of ivermectin in the treatment of moderate coronavirus disease 2019 (COVID-19) is controversial. We performed an open label randomized controlled trial to evaluate the role of ivermectin plus favipiravir-based standard of care versus favipiravir-based standard of care for the tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarojvisut, Phahol, Apisarnthanarak, Anucha, Jantarathaneewat, Kittiya, Sathitakorn, Ornnicha, Pienthong, Thanus, Mingmalairak, Chatchai, Warren, David K, Weber, David J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Infectious Diseases; Korean Society for Antimicrobial Therapy; The Korean Society for AIDS 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079435/
https://www.ncbi.nlm.nih.gov/pubmed/36603821
http://dx.doi.org/10.3947/ic.2022.0127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079435/
https://www.ncbi.nlm.nih.gov/pubmed/36603821
http://dx.doi.org/10.3947/ic.2022.0127

Ejemplares similares